Search

Your search keyword '"Helen Huls"' showing total 159 results

Search Constraints

Start Over You searched for: Author "Helen Huls" Remove constraint Author: "Helen Huls"
159 results on '"Helen Huls"'

Search Results

51. Individual motile CD4+ T cells can participate in efficient multi-killing through conjugation to multiple tumor cells

52. Sleeping Beauty Transposition of Chimeric Antigen Receptors Targeting Receptor Tyrosine Kinase-Like Orphan Receptor-1 (ROR1) into Diverse Memory T-Cell Populations

53. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals

54. Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation

55. In vivoexpansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation

56. Add-back of allodepleted donor T cells to improve immune reconstitution after haplo-identical stem cell transplantation

57. The Generation and Characterization of LMP2-Specific CTLs for Use as Adoptive Transfer From Patients With Relapsed EBV-Positive Hodgkin Disease

58. 278. Next-Generation Non-Viral Gene Transfer to Redirect T-Cell Specificity

59. A strategy for treatment of Epstein–Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells

60. Large-Scale Expansion of Dendritic Cell-Primed Polyclonal Human Cytotoxic T-Lymphocyte Lines Using Lymphoblastoid Cell Lines for Adoptive Immunotherapy

61. Autologous Epstein-Barr virus (EBV)–specific cytotoxic T cells for the treatment of persistent active EBV infection

62. Generation of EBV-Specific CD4+ Cytotoxic T Cells from Virus Naive Individuals

63. Tumor lysing genetically engineered T cells loaded with multi-modal imaging agents

64. Driving CAR-based T-cell therapy to success

65. GENERATION OF AUTOLOGOUS EPSTEIN-BARR VIRUS???SPECIFIC CYTOTOXIC T CELLS FOR ADOPTIVE IMMUNOTHERAPY IN SOLID ORGAN TRANSPLANT RECIPIENTS1

66. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation

67. PET imaging of T cells derived from umbilical cord blood

68. Genetically modified artificial antigen-presenting cells (aAPC) for expansion of melanoma tumor infiltrating lymphocytes with optimal properties for adoptive cell therapy

69. Toward eliminating HLA class I expression to generate universal cells from allogeneic donors

70. Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood

71. Prompt versus preemptive intervention for EBV lymphoproliferative disease

72. Redirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123+ Tumors

73. Abstract A179: Ex vivo generation of clinical grade T cells by using activating and propagating feeder cells to cross-link T cell receptor

74. Abstract A193: Bioengineered Dectin-1 CAR+ T cells to control invasive fungal infection

75. Abstract B053: Designing chimeric antigen receptors for personalized immunotherapy: Rapid assembly of CARs from principal components using 'EZ-CAR' platform

76. A new approach to simultaneously quantify both TCR α- and β-chain diversity after adoptive immunotherapy

77. Adoptive T-cell therapy improves treatment of canine non–Hodgkin lymphoma post chemotherapy

78. Production of good manufacturing practice-grade cytotoxic T lymphocytes specific for Epstein–Barr virus, cytomegalovirus and adenovirus to prevent or treat viral infections post-allogeneic hematopoietic stem cell transplant

79. Pre-Emptive Donor Lymphocyte Infusion with CD19-Directed, CAR-Modified T Cells Infused after Allogeneic Hematopoietic Cell Transplantation for Patients with Advanced CD19+ Malignancies

80. Infusing CD19-Directed T Cells to Augment Disease Control in Patients Undergoing Autologous Hematopoietic Stem-Cell Transplantation for Advanced B-Lymphoid Malignancies

81. Genetically Modified T Cells Targeting Interleukin-11 Receptor α-Chain Kill Human Osteosarcoma Cells and Induce the Regression of Established Osteosarcoma Lung Metastases

82. Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells

83. Genetic Reprogramming and Editing of T Cells Using the Sleeping Beauty System and Designer Zinc Finger Nucleases

85. A high throughput microelectroporation device to introduce a chimeric antigen receptor to redirect the specificity of human T cells

86. 526. Innovative Dual CAR-T Cells to Target B-Cell Leukemia and Opportunistic Fungal Agents

87. Combining CD19 redirection and alloanergization to generate tumor-specific human T cells for allogeneic cell therapy of B-cell malignancies

88. Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma

89. Large scale generation of genetically modified T-cells using micro-electroporators for cancer treatments

90. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

91. Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients

92. Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system

93. Isolation and immortalization of lymphocytes

94. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer

95. 526. Innovative Dual CAR-T Cells to Target B-Cell Leukemia and Opportunistic Fungal Agents

96. IM-07 * NK CELL IMMUNOTHERAPY FOR PEDIATRIC BRAIN TUMORS: OVERCOMING RESISTANCE TO EXPAND THERAPEUTIC SUCCESS

97. Administration of latent membrane protein 2-specific cytotoxic T lymphocytes to patients with relapsed Epstein-Barr virus-positive lymphoma

98. The clinical use of LMP2-specific cytotoxic T lymphocytes for the treatment of relapsed EBV +ve Hodgkin disease (HD) and non-Hodgkin lymphoma (NHL)

99. Specifically Targeting the Interface Between HER1-HER3 Heterodimer on Breast Cancer to Limit Off-Target Effects Using Chimeric Antigen Receptor Designs with Improved T-Cell Energy Balance

100. T-Cell Therapy for Multiple Myeloma Using NY-ESO-1+ T-Cell Antigen Presenting Cells (T-APC) Combined with Adoptive Cellular Transfer (ACT) to Augment Immunotherapy

Catalog

Books, media, physical & digital resources